By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
AdkhabarAdkhabarAdkhabar
Notification Show More
Font ResizerAa
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Reading: Premier Health of America Announces Grant of Management Cease Trade Order
Share
Font ResizerAa
AdkhabarAdkhabar
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Search
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Follow US
Adkhabar > Blog > Health > Premier Health of America Announces Grant of Management Cease Trade Order
Premier Health of America Announces Grant of Management Cease Trade Order
Health

Premier Health of America Announces Grant of Management Cease Trade Order

GlobeNews Wire
Last updated: 07/06/2026 6:37 PM
GlobeNews Wire
Published: 07/06/2026
Share
SHARE

MONTREAL, June 05, 2026 (GLOBE NEWSWIRE) — PREMIER HEALTH OF AMERICA INC. (TSX-V: PHA) (“Premier Health”, or the “Company”) announces that, further to its press release dated June 2, 2026, the Autorité des marchés financiers, as the Company’s principal regulator, has granted a management cease trade order (the “MCTO”) under National Policy 12-203 – Management Cease Trade Orders.

As previously announced, the Company’s unaudited interim financial statements and the related management’s discussion and analysis for the quarter ended March 31, 2026 (the “Required Filings”) were not filed by June 1, 2026, being the filing deadline prescribed under applicable Canadian securities law requirements.

The MCTO prohibits the Company’s Interim Chief Executive Officer, the Interim Chief Financial Officer and the members of the Board of Directors from trading securities of the Company for so long as the Required Filings remain outstanding. The issuance of the MCTO does not affect the ability of persons other than insiders of the Company to trade in the Company’s securities.

The Company currently expects to file the Required Filings on or before June 30, 2026, and will issue a press release announcing completion of such filings once completed. Until the Company files the Required Filings, it will comply with the alternative information guidelines set out in National Policy 12-203 – Management Cease Trade Orders. These guidelines require the Company to issue bi-weekly default status reports by way of press release during the period of the MCTO.

Following the June 2, 2026, press release, the Company is currently in default under its credit facilities. No new forbearance agreement is currently being negotiated and the Company continues to assess its available options.

About Premier Health

Premier Health is a leading Canadian Healthtech company that provides a comprehensive range of outsourced services solutions for healthcare needs to governments, companies, and individuals. Premier Health uses its proprietary LiPHe® platform to lead the digital transformation of the healthcare services sector, providing patients with faster, more affordable, and more accessible care.

For Further Information Please Contact:

Mr. Guy D’Aoust
Interim Chief Executive Officer
Premier Health of America Inc.
gdaoust@premierhealth.ca / 1 800 231 9916
Mr. Frédéric St-Cyr
Interim Chief Financial Officer
Premier Health of America Inc.
fstcyr@premierhealth.ca / 1 800 231 9916
WhiteSwell Announces Primary Clinical Trial Results Simultaneously at Heart Failure 2026 Congress and in European Journal of Heart Failure related to the DELTA-HF Study in Acute Decompensated Heart Failure
[Ad hoc announcement pursuant to Art. 53 LR] Roches divarasib shows superiority in head-to-head phase III trial against approved KRAS G12C inhibitors in non-small cell lung cancer
Every Smile Is Special: Sparkling Charms Dental Studio Highlights Sensory-Friendly Pediatric Dental Program for Children With Special Needs in Baltimore
ONWARD Medical Drives Strong US ARC-EX Adoption and Achieves Important Scientific and Regulatory Milestones in Q3 2025
ORIC Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025
TAGGED:CA74052G1063TSX-V:PHA
Share This Article
Facebook Email Print
- Advertisement -

Follow US

Find US on Social Medias
FacebookLike
XFollow
YoutubeSubscribe

Weekly Newsletter

Subscribe to our newsletter to get our newest articles instantly!
Popular News
The 3D-Flow Architecture Breakthrough: A Universal, Scalable Digital Processor for Real-Time Pattern Recognition in High-Rate Data Streams  A Platform to Save Millions of Lives and Billions of Euros
Health

The 3D-Flow Architecture Breakthrough: A Universal, Scalable Digital Processor for Real-Time Pattern Recognition in High-Rate Data Streams A Platform to Save Millions of Lives and Billions of Euros

GlobeNews Wire
GlobeNews Wire
20/12/2025
Casio to Release G-SHOCK with Heart Rate Monitoring and Tide Graph Functions
NYSE Content Advisory: Pre-Market update + S&P 500 hits 28th record in 2025
Derila Ergo Pillow Reviews Real Results, Benefits, Side Effects & Why the Derila Pillow Is Worth It for Pain-Free Sleep
NYSE Content Update: Brazilian Fintech AGI to Open for Trade
- Advertisement -
- Advertisement -
- Advertisement -

Categories

  • Automobile
  • Entertainment
  • E-Sports
  • Food
  • Health
  • Technology
  • LifeStyle
  • Travel

About Us

Through our news networks, we raise millions of users' awareness. We are among the world's most reputable news networks.
Quick Link
Top Categories
  • Entertainment

Subscribe US

Subscribe to our newsletter to get our newest articles instantly!

AdkhabarAdkhabar
Copyright © 2021 - 2025 AdKhabar. All Rights Reserved. POWERED BY Life Care News.
Join Us!
Subscribe to our newsletter and never miss our latest news, podcasts etc..
Zero spam, Unsubscribe at any time.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?